SCHEMBL1237641

SCHEMBL1237641

CC(=O)c1c(O)cccc1Cl

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.71
ALDH1A1 P00352 2/20 0.52
CA12 O43570 4/20 0.48
CA1 P00915 4/20 0.48
CA2 P00918 4/20 0.48
CA7 P43166 4/20 0.48
CA9 Q16790 4/20 0.48
CA14 Q9ULX7 4/20 0.48
TSHR P16473 1/20 0.48
SPR P35270 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAOB P27338 1/20 0.41
HPGD P15428 3/20 0.41
CYP3A4 P08684 1/20 0.41
FEN1 P39748 1/20 0.41
NPC1 O15118 1/20 0.40
GLA P06280 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29593170 1.00 THRB (0.71) THRBALDH1A1CA12CA1CA2
SCHEMBL976845 0.86 ALDH1A1 (0.61) THRBALDH1A1TSHRHPGDCYP3A4
SCHEMBL105807 0.84 THRB (1.00) THRBALDH1A1CA12CA1CA2
SCHEMBL330729 0.80 CA12 (0.70) THRBALDH1A1CA12CA1CA2
SCHEMBL30978346 0.80 THRB (0.54) THRBALDH1A1CA12CA1CA2
SCHEMBL17329160 0.78 ALDH1A1 (0.52) THRBALDH1A1CA12CA1CA2
SCHEMBL23409524 0.78 TSHR (0.48) THRBALDH1A1CA12CA1CA2
SCHEMBL29971128 0.78 TSHR (0.48) THRBALDH1A1CA12CA1CA2
SCHEMBL13100052 0.78 ALDH1A1 (0.52) THRBALDH1A1KMT2AHPGDFEN1
SCHEMBL3785600 0.78 ALDH1A1 (0.52) THRBALDH1A1TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
US-10941162-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2021-03-09 US disclosed
US-10919914-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2021-02-16 US disclosed
WO-2020132603-A2 SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2020-06-25 WO disclosed
US-20190330240-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TWELVE THERAPEUTICS, INC. 2019-10-31 US disclosed
US-20190135833-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TWELVE THERAPEUTICS, INC. 2019-05-09 US disclosed
WO-2011047481-A1 NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2011-04-28 WO disclosed
WO-2011011872-A1 NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2011-02-03 WO disclosed
WO-2010094120-A1 NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2010-08-26 WO disclosed
CN-1088578-C Oral compositions PROCTER & GAMBLE (US) 2002-08-07 CN disclosed
CN-1170349-A oral composition PROCTER & GAMBLE (US) 1998-01-14 CN disclosed
CN-1170350-A Oral compositions PROCTER & GAMBLE (US) 1998-01-14 CN disclosed
CN-1170348-A oral composition PROCTER & GAMBLE (US) 1998-01-14 CN disclosed
US-5519023-A SCHIZOPHRENIA ADIR ET COMPAGNIE (FR) 1996-05-21 US disclosed
EP-0580503-B1 Aminoalkylchromones, process for their preparation and compositions containing them ADIR (FR) 1995-06-14 EP disclosed
EP-0580503-A1 Aminoalkylchromones, process for their preparation and compositions containing them ADIR ET COMPAGNIE (FR) 1994-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10919914-B2 Heterocyclic compounds and uses thereof PIK3CA, PIK3CD, PIK3CB THRB 2231/4885ALDH1A1 3154/4885CA12 4339/4885
US-20190135833-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB THRB 2231/4885ALDH1A1 3154/4885CA12 4339/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB THRB 2013/4885ALDH1A1 2667/4885CA12 1610/4885
US-10941162-B2 Heterocyclic compounds and uses thereof PIK3CA, PIK3CD, PIK3CB THRB 1946/4885ALDH1A1 2938/4885CA12 4831/4885
US-20190330240-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB THRB 2231/4885ALDH1A1 3154/4885CA12 4339/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB THRB 3892/4885ALDH1A1 3142/4885CA12 4035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.